Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Lenčová Popelová, Olga ^a   Jirkovský, Eduard ^a   Mazurová, Yvona ^a   Lenčo, Juraj ^b,c   Adamcová, Michaela ^a   Šimůnek, Tomáš ^c   Geršl, Vladimír ^a   Štěrba, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; ANTHRACYCLINE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DAUNORUBICIN; PROTEASOME; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SCLEROPROTEIN; SODIUM CALCIUM EXCHANGE PROTEIN; TRANSCRIPTION FACTOR GATA 4; TROPONIN T; UBIQUITIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; FOLLOW UP; GENE EXPRESSION REGULATION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART RIGHT VENTRICLE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOREACTIVITY; MALE; MOLECULAR DIAGNOSIS; MORPHOLOGY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; ANIMAL; DRUG EFFECTS; ECHOCARDIOGRAPHY; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT; METABOLISM; PHYSIOLOGY; TOXICITY; WESTERN BLOTTING;

ANIMALS; ANTHRACYCLINES; BLOTTING, WESTERN; DAUNORUBICIN; ECHOCARDIOGRAPHY; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENTS; MALE; MYOCARDIUM; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TROPONIN T; VENTRICULAR REMODELING;

EID: 84900554427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096055     Document Type: Article

References (51)

1. Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5: 791-809. (Pubitemid 44669494)
2. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, et al. (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11 Suppl 1: S21-36.
3. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717. (Pubitemid 10218041)
4. Van Vleet JF, Ferrans VJ (1980) Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res 41: 1462-1469. (Pubitemid 11249442)
5. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872. (Pubitemid 8377880)
6. Berry GJ, Jorden M (2005) Pathology of radiation and anthracycline cardiotoxicity. Pediatr Blood Cancer 44: 630-637. (Pubitemid 40629213)
7. Van Vleet JF, Ferrans VJ, Weirich WE (1980) Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 99: 13-42.
8. Rhoden W, Hasleton P, Brooks N (1993) Anthracyclines and the Heart. Br Heart J 70: 499-502. (Pubitemid 24009959)
9. Herman EH, Ferrans VJ (1998) Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 25: 15-21. (Pubitemid 28460379)
10. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, et al. (2013) Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 18: 899-929.
11. Vejpongsa P, Yeh ET (2013) Topoisomerase 2beta: A Promising Molecular Target for Primary Prevention of Anthracycline-induced Cardiotoxicity. Clin Pharmacol Ther doi: 10.1038/clpt.2013.201.
12. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53: 105-113.
13. Boucek RJ, Jr., Miracle A, Anderson M, Engelman R, Atkinson J, et al. (1999) Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 31: 1435-1446. (Pubitemid 29361111)
14. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, et al. (1990) Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A 87: 4275-4279.
15. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M (2004) Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 101: 6975-6980. (Pubitemid 38596428)
16. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, et al. (1997) A novel cardiac-restricted target for doxorubicin - CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 272: 22800-22808. (Pubitemid 27386100)
17. Kobayashi S, Volden P, Timm D, Mao K, Xu XM, et al. (2010) Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte Death. J Biol Chem 285: 793-804.
18. Chen B, Zhong L, Roush SF, Pentassuglia L, Peng XY, et al. (2012) Disruption of a GATA4/Ankrd1 Signaling Axis in Cardiomyocytes Leads to Sarcomere Disarray: Implications for Anthracycline Cardiomyopathy. Plos One 7.
19. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, et al. (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279: 8290-8299. (Pubitemid 38294721)
20. Li YF, Wang XJ (2011) The role of the proteasome in heart disease. Biochim Biophys Acta 1809: 141-149.
21. Institute of Laboratory Animal Research CoLS, National Research Council (1996) Guide for the Care and Use of Laboratory Animals. Washington: The National Academies Press.
22. Popelova O, Sterba M, Haskova P, Simunek T, Hroch M, et al. (2009) Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 101: 792-802.
23. Simunek T, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, et al. (2004) Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail 6: 377-387. (Pubitemid 38746579)
24. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
25. Tatsumi R, Hattori A (1995) Detection of giant myofibrillar proteins connectin and nebulin by electrophoresis in 2% polyacrylamide slab gels strengthened with agarose. Anal Biochem 224: 28-31.
26. Reddy GK, Enwemeka CS (1996) A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29: 225-229. (Pubitemid 26142071)
27. Ewer MS, Benjamin RS (2006) Doxorubicin Cardiotoxicity: Clinical Apect, Recognition, Monitoring, Treatment, and Prevention. In: Ewer MS, Yeh E, editors. Cancer and the Heart. Hamilton: BC Decker. 9-32.
28. Sterba M, Popelova O, Lenco J, Fucikova A, Brcakova E, et al. (2011) Proteomic insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol 50: 849-862.
29. Moretti A, Weig HJ, Ott T, Seyfarth M, Holthoff HP, et al. (2002) Essential myosin light chain as a target for caspase-3 in failing myocardium. Proc Natl Acad Sci U S A 99: 11860-11865. (Pubitemid 34994489)
30. Hernandez OM, Jones M, Guzman G, Szczesna-Cordary D (2007) Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 292: H1643-H1654. (Pubitemid 46572386)
31. De Beer EL, Bottone AE, van der Velden J, Voest EE (2000) Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol Pharmacol 57: 1152-1157. (Pubitemid 30354386)
32. Gupta MP (2007) Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 43: 388-403.
33. Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, et al. (1998) Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 30: 243-254. (Pubitemid 28116304)
34. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, et al. (2004) Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res 95: 708-716. (Pubitemid 39331931)
35. Miller MK, Bang ML, Witt CC, Labeit D, Trombitas C, et al. (2003) The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family of titin filament-based stress response molecules. J Mol Biol 333: 951-964. (Pubitemid 37324498)
36. Torrado M, Lopez E, Centeno A, Castro-Beiras A, Mikhailov AT (2004) Left-right asymmetric ventricular expression of CARP in the piglet heart: regional response to experimental heart failure. Eur J Heart Fail 6: 161-172. (Pubitemid 38249359)
37. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, et al. (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63: 368-377. (Pubitemid 36158372)
38. Li L, Takemura G, Li Y, Miyata S, Esaki M, et al. (2006) Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113: 535-543.
39. Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, et al. (2008) Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19: 1160-1165. (Pubitemid 351796343)
40. Eghbali M, Czaja MJ, Zeydel M, Weiner FR, Zern MA, et al. (1988) Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol 20: 267-276.
41. Chapman D, Weber KT, Eghbali M (1990) Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 67: 787-794. (Pubitemid 20315010)
42. Villarreal FJ, Dillmann WH (1992) Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 262: H1861-1866.
43. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH (2000) CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 32: 1805-1819.
44. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, et al. (2006) Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 290: H1098-1102.
45. Luchner A, Muders F, Dietl O, Friedrich E, Blumberg F, et al. (2001) Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res 51: 601-607. (Pubitemid 32718609)
46. Simunek T, Sterba M, Holeckova M, Kaplanova J, Klimtova I, et al. (2005) Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals 18: 163-169. (Pubitemid 40569224)
47. Goldstein JA (2002) Pathophysiology and management of right heart ischemia. J Am Coll Cardiol 40: 841-853.
48. Walker LA, Buttrick PM (2009) The right ventricle: biologic insights and response to disease. Curr Cardiol Rev 5: 22-28.
49. Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, et al. (2003) Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell 5: 877-889. (Pubitemid 37527688)
50. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA (2004) Right ventricular myocardium derives from the anterior heart field. Circ Res 95: 261-268. (Pubitemid 39056286)
51. Milani-Nejad N, Janssen PM (2014) Small and large animal models in cardiac contraction research: advantages and disadvantages. Pharmacol Ther 141: 235-249.